Retrospective Cohort Study of Acute Ischemic Stroke Patients Treated with Alteplase

130 acute ischemic stroke patients treated with intravenous alteplase thrombolysis within 4.5 hours of symptom onset, analyzed in a retrospective study from November 2021 to December 2024. Jingxian Ni authored this research, which links higher serum uric acid levels (>360 μmol/L) to improved 90-day functional outcomes. The dataset includes baseline demographics, clinical characteristics, neuroimaging findings, and 90-day modified Rankin Scale scores.

Use Cases

• Predicting excellent 90-day functional outcomes (mRS 0-1) based on serum uric acid levels and baseline characteristics.
• Analyzing the association between serum uric acid levels and favorable outcomes (mRS 0-2) in thrombolysis patients.
• Investigating potential confounders in the relationship between hyperuricemia and stroke recovery using multivariable logistic regression.
• Studying the lack of association between serum uric acid levels and adverse events like intracranial hemorrhage or mortality.

Strengths

• Includes data for 130 patients with a clear outcome measure (90-day modified Rankin Scale).
• Study period spans over 3 years (November 2021 to December 2024), providing a temporal cohort.
• Analysis adjusted for potential confounders, and results include specific odds ratios and confidence intervals (e.g., adjusted OR: 2.690).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect single-hospital bias inherent to the study's retrospective design.

Provenance

Source

Jingxian Ni

Collection Method

Retrospective cohort study analyzing patient records from a single hospital.

Time Range

November 2021 to December 2024

Freshness

Last updated 2026-03-17 13:20:26; freshness should be verified.

Geography

null